ePT--the Electronic Newsletter of Pharmaceutical Technology, Nov 8, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
ePT--the Electronic Newsletter of Pharmaceutical Technology, Nov 8, 2012
News
Watson Completes Acquisition of Actavis, Will Take Actavis Name
By Patricia Van Arnum
Watson Pharmaceuticals has completed its EUR 4.25 billion ($5.4 billion) acquisition of the Actavis Group. The combination creates the world's third largest generic-drug pharmaceutical company, with anticipated pro forma combined 2012 revenues in excess of $8 billion, according to Watson.
Boehringer Ingelheim Settles False Claims Act Allegations for $95 Million
By Amy Ritter
Boehringer Ingelheim has agreed to pay $95 million to settle allegations that it improperly promoted four of its drugs.
USP Changes Heparin Labeling Requirement
By Susan Haigney
USP revises labeling requirements for Heparin.
EC Approves Europe's First Gene Therapy
By Stephanie Sutton
The European Commission has issued final approval for Europe's first gene therapy—a treatment for a rare genetic disorder that currently has no other treatment options.
Week of November 5, 2012: Merck & Co. Resolves Vioxx Lawsuit; Takeda Agrees to Acquire Envoy Therapeutics; and More
Merck & Co. Resolves Vioxx Lawsuit; Takeda Agrees to Acquire Envoy Therapeutics; and More.
Regulatory Roundup for Week of November 5, 2012
FDA pushes back goals due to Hurricane Sandy and EMA announces changes to variation regulations.

ADVERTISEMENT
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What is the single greatest threat to maintaining manufacturing processes at your facility?
Quality issues
Facility/environment problems
Process development problems
Production equipment downtime
Raw material supply problems
Regulatory restrictions
Business decisions to limit production
Quality issues
100%
Facility/environment problems
0%
Process development problems
0%
Production equipment downtime
0%
Raw material supply problems
0%
Regulatory restrictions
0%
Business decisions to limit production
0%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Click here